From Davids to Goliaths: the GLP-1R gold rush
Drugs targeting the glucagon-like peptide-1 receptor (GLP-1R) demonstrated remarkable success in 2023, with approved products generating sales of $37.2 billion. Currently, there are 323 active
Drugs targeting the glucagon-like peptide-1 receptor (GLP-1R) demonstrated remarkable success in 2023, with approved products generating sales of $37.2 billion. Currently, there are 323 active
Karie Bostwick, VP of People and Compliance, Revenue Enterprises The Consumer Financial Protection Bureau (CFPB) has announced that it wants to ban the inclusion of
Interactions with friends and family may keep us healthy because they boost our immune system and reduce our risk of diseases such as heart disease,
A genetic fault long believed to drive the development of esophageal cancer may in fact play a protective role early in the disease, according to
The Phase I trial of the therapy with 20 healthy subjects indicated no drug-related serious adverse events. Credit: Mongkolchon Akesin/Shutterstock. SIGA Technologies has gained Japanese
In Pawtucket, Rhode Island, near a storefront advertising “free” cellphones, J.R. sat in an empty back stairwell and showed a reporter how he tries to
More than three years have passed since federal health officials arrived in central Appalachia to assess an alarming outbreak of HIV spread mostly between people
The study indicates that e-cigarettes might reduce smoking-related respiratory symptoms, yet further research is essential to understand long-term effects.
As 2025 begins, we are living in a Groundhog Day of distrust in clinical AI with potentially disastrous outcomes. About two years ago one of
Life was getting better for Carlos Campos, 72, a retired machinist who lives with his wife and daughter in Tukwila, Wash. Diagnosed about 20 years